# Daratumumab in Treating Patients With Multiple Myeloma

> **NCT02944565** · PHASE2 · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 28 (actual)

## Conditions studied

- Plasma Cell Myeloma

## Interventions

- **BIOLOGICAL:** Daratumumab

## Key facts

- **NCT ID:** NCT02944565
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-22
- **Primary completion:** 2017-07-20
- **Final completion:** 2017-07-20
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2019-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02944565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02944565, "Daratumumab in Treating Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02944565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*